What are the indications, eligibility criteria, and standard regimen for intraperitoneal (IP) chemotherapy in newly diagnosed stage III epithelial ovarian, fallopian tube, or primary peritoneal cancer after optimal cytoreductive surgery?

Intraperitoneal Chemotherapy in Ovarian Cancer

Intraperitoneal (IP) chemotherapy is a Category 1 recommendation for selected patients with newly diagnosed stage III epithelial ovarian, fallopian tube, or primary peritoneal cancer who have undergone optimal cytoreductive surgery with residual disease <1 cm 1, 2.

Eligibility Criteria

Patient Selection:

• Stage III disease (optimally debulked with <1 cm residual disease) 1, 2
• Good performance status (patients with poor performance status should receive IV therapy instead) 2
• Stage II disease may also be considered, though this is Category 2A due to lack of randomized evidence 1

Key Exclusion Considerations:

• Poor performance status
• Patients at high risk for neuropathy (e.g., diabetes) may be better suited for alternative regimens like docetaxel/carboplatin 2

Standard IP Regimen

The NCCN Category 1 regimen consists of:

• Day 1: Paclitaxel 135 mg/m² IV continuous infusion over 24 hours
• Day 2: Cisplatin 75-100 mg/m² IP (after IV paclitaxel)
• Day 8: Paclitaxel 60 mg/m² IP
• Repeat every 3 weeks for 6 cycles 1, 2

Important modifications to reduce toxicity:

• The published trials used 24-hour IV paclitaxel infusion, but 3-hour infusions are more convenient and less toxic, though not formally compared in trials 1
• Lower IP cisplatin doses (75 mg/m²) may reduce toxicity 1
• Previously, doses were capped at BSA 2.0 m², but this restriction was removed in 2013 1

Survival Benefit

The evidence demonstrates significant survival advantages:

• Overall survival increased by 16 months (65.6 vs 49.7 months, P=0.03) in the GOG 172 trial comparing IP to IV therapy 2
• Progression-free survival improved from 18.3 to 23.8 months (P=0.05) 3
• Meta-analysis confirms reduced mortality (HR 0.81,95% CI 0.72-0.90) and improved disease-free survival (HR 0.78,95% CI 0.70-0.86) 4

Toxicity Profile and Completion Rates

Critical caveats about IP chemotherapy:

• Only 42% of patients completed all 6 cycles in GOG 172 3
• Grade 3-4 toxicities are significantly more common than IV therapy, including:
  • Pain, fatigue
  • Hematologic toxicity
  • Gastrointestinal effects
  • Metabolic complications
  • Neurologic effects 3
• Catheter-related complications occur in approximately 20% of patients, potentially requiring port removal 5
• Quality of life is significantly worse during treatment but equalizes by 1 year post-treatment 3

Modified outpatient regimens have shown improved tolerability:

• Modified protocols using 3-hour IV paclitaxel and lower cisplatin doses (75 mg/m²) achieve 72.5-85.7% completion rates with reduced toxicity 5, 6

Current Clinical Context

The role of IP chemotherapy has evolved significantly:

• The GOG 252 trial (referenced in newer guidelines) showed no superiority of IP chemotherapy over dose-dense IV regimens, leading many centers to abandon routine IP use 7
• The rise of maintenance PARP inhibitors (olaparib, niraparib) and bevacizumab has shifted treatment paradigms, as these agents provide survival benefits with different toxicity profiles 8, 9
• Most contemporary practice has moved away from adjuvant normothermic IP chemotherapy in favor of IV chemotherapy followed by targeted maintenance therapy 7

Alternative to Traditional IP: HIPEC

Hyperthermic intraperitoneal chemotherapy (HIPEC) at interval surgery:

• For patients with stage IIIC disease initially deemed unresectable who undergo neoadjuvant chemotherapy
• HIPEC with cisplatin 100 mg/m² at interval debulking surgery (after achieving <1 cm residual disease) showed improved recurrence-free and overall survival in the OVHIPEC-1 trial 10, 7
• This is Grade B recommendation for selected patients with optimal interval cytoreduction 10

Practical Algorithm for Decision-Making

For newly diagnosed stage III optimally debulked ovarian cancer:

1. If residual disease <1 cm AND good performance status AND patient accepts higher toxicity for survival benefit:

   • Consider IP chemotherapy (Category 1) 1, 2
   • Discuss 16-month survival advantage vs. significant toxicity and 58% discontinuation rate
   • Ensure experienced team and appropriate patient counseling

2. If poor performance status OR high neuropathy risk OR patient preference for better tolerability:

   • Use IV paclitaxel/carboplatin (Category 1) 1, 2
   • Consider dose-dense weekly paclitaxel regimen (Category 1) 1
   • Add bevacizumab if appropriate (Category 1 for stage III-IV) 1
   • Follow with maintenance PARP inhibitor if BRCA-mutated or HRD-positive 8, 9

3. If initially unresectable stage IIIC requiring neoadjuvant chemotherapy:

   • Consider HIPEC at interval debulking if optimal cytoreduction achieved 10, 7

The efficacy/toxicity ratio must be carefully individualized, with most contemporary centers favoring IV chemotherapy plus targeted maintenance therapy over traditional IP approaches 7.